MARKET

IPSC

IPSC

Century Therapeutics, Inc.
NASDAQ
2.020
-0.040
-1.94%
After Hours: 2.094 +0.074 +3.67% 17:31 03/27 EDT
OPEN
2.020
PREV CLOSE
2.060
HIGH
2.049
LOW
1.934
VOLUME
1.55M
TURNOVER
--
52 WEEK HIGH
3.040
52 WEEK LOW
0.3418
MARKET CAP
363.04M
P/E (TTM)
-18.2475
1D
5D
1M
3M
1Y
5Y
1D
Century Therapeutics Updates ATM Program to Enhance Liquidity
TipRanks · 2d ago
Century Therapeutics Maintains $150M ATM Program, With $131.6M Remaining In Capacity
Benzinga · 2d ago
Century Therapeutics updates $150.0 million ATM program; $131.6 million remains available for sale
Reuters · 2d ago
CENTURY THERAPEUTICS INC - MAY OFFER UP TO $150 MLN IN COMMON STOCK THROUGH TD COWEN - SEC FILING
Reuters · 2d ago
Top performing small-cap stocks YTD as volatility hits markets
Seeking Alpha · 5d ago
Weekly Report: what happened at IPSC last week (0316-0320)?
Weekly Report · 5d ago
Century Therapeutics Rocked by Dual Insider Moves at the Top
TipRanks · 03/17 02:08
iSpecimen Collects 500 Influenza Samples, Showcases Rapid Research Support
Benzinga · 03/16 11:50
More
About IPSC
Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies and autoimmune diseases. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-308, CNTY-341, CNTY-107, and CNTY-104. Its lead product candidate CNTY-101 is a CAR-iNK cell therapy with six precision gene edits in a Phase I clinical trial for patients with B-cell mediated autoimmune diseases. CNTY-308 is a CD19-targeted, iPSC derived CAR T cell therapy. CNTY-341 is a dual-targeted CD19 and CD22 iPSC-derived CAR-T cell therapy.

Webull offers Century Therapeutics Inc stock information, including NASDAQ: IPSC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IPSC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IPSC stock methods without spending real money on the virtual paper trading platform.